Cryotherapy option for prostate cancer treatment

23 May 2008

Galil Medical has announced that the American Urological Association has introduced clinical guidelines with best practice statements for prostate cryotherapy. The guidelines state that cryoablation is a treatment option for men with clinically confined prostate cancer of any grade and that salvage cryoablation is a treatment option in men who have failed radiation therapy.

Prostate cryotherapy uses extreme cold to freeze and destroy prostate cancer cells. This minimally invasive procedure is routinely and successfully performed on prostate cancer patients with varying disease stages as well as those who have failed radiation treatment.

Prostate cancer is the most common cancer, other than skin cancers, in American men. The American Cancer Society estimates that during 2008 about 186,320 new cases of prostate cancer will be diagnosed in the United States.

Dr Richard Babaian, Professor and Senior Medical Director at the MD Anderson Physician Network, presented the new guidelines for cryotherapy for the treatment of localized prostate cancer at the plenary session of the AUA annual meeting.

Martin J. Emerson, Galil Medical President and CEO comments, "We are pleased that the AUA, in its pre-eminent role in assessing new treatment options for urologists and their patients, now recognizes cryotherapy as a mainstream treatment option for patients diagnosed with localized prostate cancer."

A recently published retrospective study of primary prostate cryotherapy by Dr Jeffrey Cohen reported 10-year follow up data with biochemical control comparable to external beam radiotherapy or prostate brachytherapy. The literature has also shown that advances over the last 10 years in cryoablation techniques have dramatically improved the morbidity profile.

New guidelines for the treatment of localized prostate cancer were released by the AUA in 2007 and emphasized communication with the patient regarding risk, treatment options, and potential outcomes. At that time, it was recognized that cryotherapy for the treatment of localized prostate cancer should be the topic of an AUA best practice policy.

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Cryotherapy option for prostate cancer treatment 23 May 2008 Galil Medical has announced that the American Urological Association has introduced clinical guidelines with best practice statements for prostate cryotherapy. The guidelines state that cryoablation is a treatment option for men with clinically confined prostate cancer of any grade and that salvage cryoablation is a treatment option in men who have failed radiation therapy. Prostate cryotherapy uses extreme cold to freeze and destroy prostate cancer cells. This minimally invasive procedure is routinely and successfully performed on prostate cancer patients with varying disease stages as well as those who have failed radiation treatment. Prostate cancer is the most common cancer, other than skin cancers, in American men. The American Cancer Society estimates that during 2008 about 186,320 new cases of prostate cancer will be diagnosed in the United States. Dr Richard Babaian, Professor and Senior Medical Director at the MD Anderson Physician Network, presented the new guidelines for cryotherapy for the treatment of localized prostate cancer at the plenary session of the AUA annual meeting. Martin J. Emerson, Galil Medical President and CEO comments, "We are pleased that the AUA, in its pre-eminent role in assessing new treatment options for urologists and their patients, now recognizes cryotherapy as a mainstream treatment option for patients diagnosed with localized prostate cancer." A recently published retrospective study of primary prostate cryotherapy by Dr Jeffrey Cohen reported 10-year follow up data with biochemical control comparable to external beam radiotherapy or prostate brachytherapy. The literature has also shown that advances over the last 10 years in cryoablation techniques have dramatically improved the morbidity profile. New guidelines for the treatment of localized prostate cancer were released by the AUA in 2007 and emphasized communication with the patient regarding risk, treatment options, and potential outcomes. At that time, it was recognized that cryotherapy for the treatment of localized prostate cancer should be the topic of an AUA best practice policy. Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.